Salix growth outlook, value compelling, says Stifel Following Salix's Analyst Day, Stifel believes that Salix's shares offer one of the most compelling growth and value opportunities among specialty drug companies it covers. The firm thinks that data for the company's Xifaxan data was strong and is likely to satisfy the FDA. The firm is upbeat on the company's Cosmo deal and thinks the deal is underappreciated. It keeps a Buy rating on Salix.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.